The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial
En palabras de los autores
Phosphatidylinositol 3-kinase delta (PI3Kδ) promotes tumour cell growth directly or indirectly by activating immune-suppressive cells. In contrast to previous PI3Kδ inhibitors, roginolisib is a selective, non-ATP competitive inhibitor, which locks PI3Kδ into an inactive state and causes an allosteric modulation. In a First-in-Human dose study, continuous daily dosing of roginolisib was investigated in patients with solid and haematologic malignancies. In Part A, 24 patients received escalating doses of roginolisib. In Part B, 20 mostly pre-treated metastatic uveal melanoma (mUM) patients received a dose associated with continuous PI3Kδ inhibition of >90%. The primary endpoint was safety, and secondary endpoints included pharmacokinetic (PK) and pharmacodynamic (PD) profile, clinical anti-tumour responses assessments. Exploratory endpoints included immunophenotyping, proteomics, genomics. No Dose Limiting Toxicity or drug related toxicities requiring dose modifications were observed ( ≥ Grade 3 toxicities: 3/44; 6.8%). In mUM, median Overall Survival (mOS) was 20.8 months (data-cut off December 2023) and 18.4 months (data-cut-off February 2026). mOS in mUM patients with Stable Disease at Week 16 ( = Cycle 5) was 28.5 months, while patients who progressed at Week 16 had a median OS of 12.3 months. Roginolisib was safe, had a predictable PK profile, T regulatory cell abundance was decreased while activated CD8+ T cells increased together with soluble plasma IL-15. ClinicalTrials.gov registration: NCT04328844. First generation inhibitors of phosphatidylinositol 3-kinase delta (PI3Kδ) had limited selectivity due to the conserved ATP binding pocket, resulting in toxicity when used as anti-cancer agent. Here, the authors report the results of a first-in-human clinical trial of Roginolisib, a next generation conformation-selective PI3Kδ inhibitor, in patients with advanced or metastatic cancer with dose expansion in patients with metastatic uveal melanoma.
En palabras simples Resumen con IA
Roginolisib es un nuevo medicamento contra el cáncer que bloquea PI3Kδ, una proteína que ayuda a los tumores a crecer, en una forma inactiva. En un ensayo de primera vez en humanos, 44 pacientes con cánceres avanzados recibieron roginolisib diariamente, incluyendo 20 con melanoma uveal metastásico. El medicamento fue seguro, con solo el 6.8% de los pacientes teniendo efectos secundarios graves y sin necesidad de reducir dosis. Los pacientes con melanoma uveal metastásico vivieron una mediana de 20.8 meses, y aquellos con enfermedad estable a las 16 semanas vivieron 28.5 meses. El medicamento disminuyó las células que suprimen el sistema inmune y aumentó las células que combaten el cáncer en los pacientes.
Escrito por Kimi K2.5 usando solo el abstract de arriba. Jev verificó que cada oración esté respaldada por las oraciones del abstract que cita y eliminó las que no. Pasá el cursor por una oración para ver de dónde sale.
Apareció: domingo, 11 de octubre. Nature Communications. Revista con revisión por pares.